Tutorials
Compass Therapeutics Inc logo

Compass Therapeutics Inc

$ 2.68 +0.01 (+0.37%) 04:00 PM EST
P/E:
At Loss
P/B:
2.15
Market Cap:
$ 271.44M
Enterprise V:
$ 141.91M
Volume:
79.15K
Avg Vol (2M):
145.25K
Volume:
79.15K
Market Cap $:
271.44M
PE Ratio:
At Loss
Avg Vol (2-Month):
145.25K
Enterprise Value $:
141.91M
PB Ratio:
2.15
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Compass Therapeutics Inc
NAICS : 541714 SIC : 2834
80 Guest Street, Suite 601, Boston, MA, USA, 02135
Description
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 37.77
Equity-to-Asset 0.91
Debt-to-Equity 0.03
Debt-to-EBITDA -0.11
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -23.3
3-Year EPS without NRI Growth Rate -27.9
3-Year FCF Growth Rate 21

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 59.32
9-Day RSI 53.28
14-Day RSI 51.56
6-1 Month Momentum % 43.69
12-1 Month Momentum % -40.11

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 12.36
Quick Ratio 12.36
Cash Ratio 12.13

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -24.6

Financials (Next Earnings Date:2022-11-11 Est.)

CMPX's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:CMPX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -0.3
Beta 0
Volatility % 130.41
14-Day RSI 51.56
14-Day ATR ($) 0.188548
20-Day SMA ($) 2.654
12-1 Month Momentum % -40.11
52-Week Range ($) 1.25 - 4.6
Shares Outstanding (Mil) 101.28

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Compass Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More